Zoetis Inc
NYSE:ZTS
Zoetis Inc
Income from Continuing Operations
Zoetis Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Zoetis Inc
NYSE:ZTS
|
Income from Continuing Operations
$2.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
17%
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
-$254m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
See Also
What is Zoetis Inc's Income from Continuing Operations?
Income from Continuing Operations
2.4B
USD
Based on the financial report for Mar 31, 2024, Zoetis Inc's Income from Continuing Operations amounts to 2.4B USD.
What is Zoetis Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
17%
Over the last year, the Income from Continuing Operations growth was 15%. The average annual Income from Continuing Operations growth rates for Zoetis Inc have been 10% over the past three years , 12% over the past five years , and 17% over the past ten years .